Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney

Morie Gertz, Nelson Leung, Martha Lacy, Angela Dispenzieri, Steven R. Zeldenrust, Suzanne R. Hayman, Francis K. Buadi, David M Dingli, Philip R. Greipp, Shaji K Kumar, John A. Lust, S Vincent Rajkumar, Stephen J Russell, Thomas Elmer Witzig

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Background. The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50 of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described.Methods. Kaplan-Meier and multivariate analyses were performed in a uniformly treated cohort of 145 patients with biopsy-proven AL who were monitored for at least 11 years. Outcome measurements were needed for renal replacement therapy and survival.Results. Among patients presenting with renal AL, 42 ultimately received renal replacement therapy versus 5 of patients who did not have this presentation. Patients with renal amyloid who received dialysis support had significantly higher serum creatinine and 24-h urine protein levels at presentation. Patients with λ light chain amyloid were significantly more likely to have renal involvement and had significantly greater urinary protein loss than patients with κ light chain amyloid. Serum creatinine level was an independent predictor of overall survival when corrected for cardiac involvement. For 38 patients who received dialysis, median survival from Day 1 of dialysis was 10.4 months, and 26 of patients with AL ultimately received renal replacement therapy versus 42 of patients who presented with renal AL specifically.Conclusions. Presenting 24-h urine protein loss and creatinine values predict which patients will require dialysis. Median survival for patients starting dialysis is <1 year. The presence of λ light chain amyloid predicts the increased likelihood of renal involvement.

Original languageEnglish (US)
Pages (from-to)3132-3137
Number of pages6
JournalNephrology Dialysis Transplantation
Volume24
Issue number10
DOIs
StatePublished - Oct 2009

Fingerprint

Immunoglobulin Light Chains
Amyloidosis
Kidney
Renal Replacement Therapy
Dialysis
Amyloid
Creatinine
Survival
Light
Urine
Proteins
Kaplan-Meier Estimate
Serum

Keywords

  • Amyloidosis
  • Dialysis
  • Immunoglobulin light chains
  • Proteinuria
  • Renal failure

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. / Gertz, Morie; Leung, Nelson; Lacy, Martha; Dispenzieri, Angela; Zeldenrust, Steven R.; Hayman, Suzanne R.; Buadi, Francis K.; Dingli, David M; Greipp, Philip R.; Kumar, Shaji K; Lust, John A.; Rajkumar, S Vincent; Russell, Stephen J; Witzig, Thomas Elmer.

In: Nephrology Dialysis Transplantation, Vol. 24, No. 10, 10.2009, p. 3132-3137.

Research output: Contribution to journalArticle

@article{99e04bd1943a44458641197f85b3d0a9,
title = "Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney",
abstract = "Background. The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50 of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described.Methods. Kaplan-Meier and multivariate analyses were performed in a uniformly treated cohort of 145 patients with biopsy-proven AL who were monitored for at least 11 years. Outcome measurements were needed for renal replacement therapy and survival.Results. Among patients presenting with renal AL, 42 ultimately received renal replacement therapy versus 5 of patients who did not have this presentation. Patients with renal amyloid who received dialysis support had significantly higher serum creatinine and 24-h urine protein levels at presentation. Patients with λ light chain amyloid were significantly more likely to have renal involvement and had significantly greater urinary protein loss than patients with κ light chain amyloid. Serum creatinine level was an independent predictor of overall survival when corrected for cardiac involvement. For 38 patients who received dialysis, median survival from Day 1 of dialysis was 10.4 months, and 26 of patients with AL ultimately received renal replacement therapy versus 42 of patients who presented with renal AL specifically.Conclusions. Presenting 24-h urine protein loss and creatinine values predict which patients will require dialysis. Median survival for patients starting dialysis is <1 year. The presence of λ light chain amyloid predicts the increased likelihood of renal involvement.",
keywords = "Amyloidosis, Dialysis, Immunoglobulin light chains, Proteinuria, Renal failure",
author = "Morie Gertz and Nelson Leung and Martha Lacy and Angela Dispenzieri and Zeldenrust, {Steven R.} and Hayman, {Suzanne R.} and Buadi, {Francis K.} and Dingli, {David M} and Greipp, {Philip R.} and Kumar, {Shaji K} and Lust, {John A.} and Rajkumar, {S Vincent} and Russell, {Stephen J} and Witzig, {Thomas Elmer}",
year = "2009",
month = "10",
doi = "10.1093/ndt/gfp201",
language = "English (US)",
volume = "24",
pages = "3132--3137",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney

AU - Gertz, Morie

AU - Leung, Nelson

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Zeldenrust, Steven R.

AU - Hayman, Suzanne R.

AU - Buadi, Francis K.

AU - Dingli, David M

AU - Greipp, Philip R.

AU - Kumar, Shaji K

AU - Lust, John A.

AU - Rajkumar, S Vincent

AU - Russell, Stephen J

AU - Witzig, Thomas Elmer

PY - 2009/10

Y1 - 2009/10

N2 - Background. The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50 of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described.Methods. Kaplan-Meier and multivariate analyses were performed in a uniformly treated cohort of 145 patients with biopsy-proven AL who were monitored for at least 11 years. Outcome measurements were needed for renal replacement therapy and survival.Results. Among patients presenting with renal AL, 42 ultimately received renal replacement therapy versus 5 of patients who did not have this presentation. Patients with renal amyloid who received dialysis support had significantly higher serum creatinine and 24-h urine protein levels at presentation. Patients with λ light chain amyloid were significantly more likely to have renal involvement and had significantly greater urinary protein loss than patients with κ light chain amyloid. Serum creatinine level was an independent predictor of overall survival when corrected for cardiac involvement. For 38 patients who received dialysis, median survival from Day 1 of dialysis was 10.4 months, and 26 of patients with AL ultimately received renal replacement therapy versus 42 of patients who presented with renal AL specifically.Conclusions. Presenting 24-h urine protein loss and creatinine values predict which patients will require dialysis. Median survival for patients starting dialysis is <1 year. The presence of λ light chain amyloid predicts the increased likelihood of renal involvement.

AB - Background. The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50 of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described.Methods. Kaplan-Meier and multivariate analyses were performed in a uniformly treated cohort of 145 patients with biopsy-proven AL who were monitored for at least 11 years. Outcome measurements were needed for renal replacement therapy and survival.Results. Among patients presenting with renal AL, 42 ultimately received renal replacement therapy versus 5 of patients who did not have this presentation. Patients with renal amyloid who received dialysis support had significantly higher serum creatinine and 24-h urine protein levels at presentation. Patients with λ light chain amyloid were significantly more likely to have renal involvement and had significantly greater urinary protein loss than patients with κ light chain amyloid. Serum creatinine level was an independent predictor of overall survival when corrected for cardiac involvement. For 38 patients who received dialysis, median survival from Day 1 of dialysis was 10.4 months, and 26 of patients with AL ultimately received renal replacement therapy versus 42 of patients who presented with renal AL specifically.Conclusions. Presenting 24-h urine protein loss and creatinine values predict which patients will require dialysis. Median survival for patients starting dialysis is <1 year. The presence of λ light chain amyloid predicts the increased likelihood of renal involvement.

KW - Amyloidosis

KW - Dialysis

KW - Immunoglobulin light chains

KW - Proteinuria

KW - Renal failure

UR - http://www.scopus.com/inward/record.url?scp=70349488292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349488292&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfp201

DO - 10.1093/ndt/gfp201

M3 - Article

C2 - 19403931

AN - SCOPUS:70349488292

VL - 24

SP - 3132

EP - 3137

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 10

ER -